ArticleCardiovascular and interventional radiology2026
A Prospective, Randomized Controlled Trial of Intravascular Ultrasound-Guided versus Digital Subtraction Angiography-Guided Mechanical Thrombectomy in Acute Intermediate-Risk and High-Risk Pulmonary Embolism.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Robotic Bronchoscopic Lung Ablation: Can Evidence Generation Keep Pace with Technological Innovation?Cardiovascular and interventional radiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeThis study aimed to compare the efficacy and safety of intravascular ultrasound (IVUS)-guided mechanical thrombectomy with those of conventional digital subtraction angiography (DSA)-guided mechanical thrombectomy in patients with intermediate- to high-risk acute pulmonary embolism. MATERIALS AND
methodsThis is a prospective, 1:1 block-randomized, controlled, open-label, blinded-endpoint (PROBE design), multi-center, superiority trial (Protocol Version 1.0, dated February 1, 2025). Eligible patients aged 18-75 years, diagnosed with intermediate-high-risk acute pulmonary embolism, with right ventricular/left ventricular diameter ratio (RV/LV) ≥ 0.9 on computed tomography pulmonary angiography (CTPA) will be included. The exclusion criteria included unsuitable vascular anatomy for the thrombectomy device; chronic pulmonary hypertension; left bundle branch block; chronic left heart failure (LVEF ≤ 30%); renal dysfunction (serum creatinine > 1.8 mg/dL or > 159 μmol/L); coagulopathy; contrast media hypersensitivity. The intervention group will undergo IVUS-guided mechanical thrombectomy using the Tendvia System (Shanghai Tendvia Medical Devices Co., Ltd.) under the guidance of a Philips IVUS system. The control group will undergo conventional DSA-guided mechanical thrombectomy using the same Tendvia System. The primary efficacy endpoint is the reduction in the RV/LV ratio from baseline to 48 h post-procedure. The primary safety endpoint is a composite of major adverse events (MAEs) within 48 h, including procedure-related mortality, major bleeding, and clinical deterioration requiring escalation of care.
Indexed as
Identifiers
42637832What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.